Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2019-10-22 M&A Activity
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma expands its peptide platform with acquisition of Encycle Therapeutics
M&A Activity Classification · 100% confidence The document is a formal company announcement regarding the acquisition of Encycle Therapeutics by Zealand Pharma. It details the strategic rationale, financial terms (up to $80 million), and the impact on the company's pipeline. Since the document describes a merger and acquisition transaction, it falls under the M&A Activity category.
2019-10-22 English
M&A Activity 2019
M&A Activity Classification · 99% confidence The document is a company announcement (No. 37 / 2019) detailing the acquisition of Encycle Therapeutics by Zealand Pharma. It outlines the strategic rationale, financial terms (up to US $80 million in contingent value rights), and includes details for an upcoming conference call to discuss the transaction. This type of announcement, concerning corporate development, financing, or material transactions, fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were a generic update. However, since it explicitly details a major transaction involving financing/deal structure (acquisition with earn-outs), 'CAP' is a strong candidate. Given the context of M&A activity, 'TAR' (M&A Activity) is also relevant, but 'CAP' often covers the financing/deal structure aspect of acquisitions. Since the core event is an acquisition, 'TAR' (Merger Proposals or Takeover Bids) is the most precise fit for an acquisition announcement, even if it's not a 'bid' but a completed agreement announcement. Reviewing the definitions: - CAP: Updates on company fundraising, financing activities, or capital structure changes. (Acquisition involves capital structure change/financing terms). - TAR: Announcements and documents related to merger proposals or takeover bids. (This is an acquisition announcement). In many classification schemes, a definitive acquisition announcement falls under M&A (TAR). I will classify it as TAR as it is the most specific category for an acquisition announcement.
2019-10-22 English
Total number of shares and voting rights in Zealand Pharma at September 30, 2019
Share Issue/Capital Change Classification · 95% confidence The document is titled "Company announcement – No. 36 / 2019" and explicitly states the purpose: "Total number of shares and voting rights in Zealand Pharma at September 30, 2019". It details changes in share capital following a private placement and warrant exercise, concluding with the final share count and voting rights as of the specified date. This type of mandatory disclosure regarding the total number of shares outstanding, often triggered by capital changes, is a specific corporate action announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS). It most closely aligns with an announcement related to capital structure changes or major shareholding notifications, but since it is a formal announcement of the total share count following capital events, it fits best under Share Issue/Capital Change (SHA) or potentially Major Shareholding Notification (MRQ) if the change crossed a threshold. Given the context of announcing the total count after capital increases (private placement and warrant exercise), SHA is the most appropriate fit, as it directly relates to the capital structure change. However, reviewing the definitions, SHA is for 'Announcement regarding new share issues, stock splits, or other capital changes.' MRQ is for 'Notification of changes in significant share ownership levels (crossing thresholds).' Since the document explicitly references prior announcements about capital increases (private placement and warrant exercise) and then reports the resulting total share count, SHA is the primary classification. It is a direct consequence of a capital change event.
2019-09-30 English
Total number of shares and voting rights in Zealand Pharma at September 30, 2019
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from Zealand Pharma regarding the total number of shares and voting rights following capital changes (private placement and warrant exercise). This type of disclosure is a standard regulatory requirement for companies to report changes in share capital and voting rights. It fits the definition of a share capital change announcement.
2019-09-30 English
Total number of shares and voting rights in Zealand Pharma at September 30, 2019
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement regarding the total number of shares and voting rights in Zealand Pharma as of September 30, 2019. It explicitly references previous announcements regarding share capital increases due to private placements and warrant exercises. This type of disclosure is a standard regulatory requirement for companies to update the market on their capital structure and share count. While it mentions share capital, it is not a report of a new share issue (SHA) or a buyback (POS), but rather a periodic disclosure of the current total. Given the nature of the disclosure as a regulatory requirement for transparency in share capital, it fits best under the 'Regulatory Filings' (RNS) category.
2019-09-30 English
Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding positive clinical trial results for a drug candidate (dasiglucagon). It follows the standard format of a press release or regulatory announcement (RNS) issued by a biotechnology company. It does not fit into specific categories like 10-K, AGM, or DIRS. While it mentions an attachment, the document itself provides the full content of the announcement, making it a primary regulatory announcement rather than just a notification of a report.
2019-09-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.